You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Addressing SDoH and Decreasing Disparities in PAH: A Focus on Technology, Tools & Advancing Therapies

  • Authors: Vallerie V. McLaughlin, MD (Chair); Jean M. Elwing, MD; Nicholas Kolaitis, MD, MAS; R. James White III, MD, PhD
  • CME Released: 3/30/2023
  • Valid for credit through: 3/30/2024
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational initiative is designed for cardiologists, pulmonologists, critical care clinicians, and primary care practitioners, including advanced practice clinicians (nurse practitioners and physician assistants) and nurses.

The goals of this activity are to

  • Update clinicians on newly refined risk assessment tools, standard of care therapy, and new clinical trial data
  • Address the social determinants of health (SDoH) that can impact treatment outcomes to better manage all patients with pulmonary arterial hypertension (PAH), including those who historically have been underserved
  • Raise awareness of methamphetamine-associated PAH

Upon completion of this activity, participants will be able to:

  1. Explain how to implement newly refined risk assessment tools, standard of care therapy and new clinical trial data into practice where appropriate
  2. Recognize the nonspecific symptoms of PAH as well as the social determinants of health (SDoH) that can impact treatment outcomes to better manage all patients with PAH, including those who historically have been underserved
  3. Develop strategies to address SDoH, including access to technologies such as broadband and telemedicine, to improve outcomes in PAH
  4. Describe the clinical presentation and outcomes of methamphetamine-associated PAH compared with those of idiopathic PAH and how SDoH can impact patient outcomes


Disclosures

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.
 


Faculty

  • Vallerie V. McLaughlin, MD

    Professor of Medicine
    Director, Pulmonary Hypertension Program
    University of Michigan Medical School
    Ann Arbor, Michigan

    Disclosures

    Vallerie V. McLaughlin, MD, has the following relevant financial relationships:
    Consultant or advisor for: Aerami; Aerovate; Altavant; Bayer; Caremark LLC; Corvista; Gossamer Bio; Janssen; Merck; United Therapeutics
    Contracted researcher for: Aerovate; Altavant; Gossamer Bio; Janssen; Merck; Sonovie

  • Jean M. Elwing, MD

    Professor of Medicine
    Division of Pulmonary, Critical Care and Sleep Medicine
    University of Cincinnati
    Cincinnati, Ohio

    Disclosures

    Jean M. Elwing, MD, has the following relevant financial relationships:
    Consultant or advisor for: Consulting Fee (e.g., Advisory Board): Acceleron/Merck; Aerovate; Altavant; Bayer; Gossamer Bio; Liquidia; Janssen; Insmed; United Therapeutics
    Contracted researcher for: Acceleron/Merck; Aerovate; Altavant; Bayer; Janssen; Liquidia; Gossamer Bio; Pharmosa; Phase Bio; Tenax; United Therapeutics

  • Nicholas Kolaitis, MD, MAS

    Professor of Medicine
    Director, Pulmonary Hypertension Program
    University of Michigan Medical School
    Ann Arbor, Michigan

    Disclosures

    Nicholas Kolaitis, MD, MAS, has the following relevant financial relationships:
    Consultant or advisor for: Consulting Fee (e.g., Advisory Board): Acceleron; Janssen; United Therapeutics

  • R. James White III, MD, PhD

    Professor of Medicine, Pharmacology, and Physiology
    School of Medicine and Dentistry
    University of Rochester Medical Center
    Rochester, New York

    Disclosures

    R. James White III, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Altavant; Bayer, Merck
    Contracted researcher for: Altavant; Bayer; Gossamer Bio; Merck; United Therapeutics

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies.

Global

The planners and managers at Global Education Group have no relevant financial relationships.

Iridium

Iridium Continuing Education staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships.


Accreditation Statements


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium Continuing Education (Iridium). Global is accredited by the ACCME to provide continuing medical education for physicians.

    For Physicians

  • Global Education Group designates this enduring material for a maximum of 1.0  AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Contact Information

    For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Addressing SDoH and Decreasing Disparities in PAH: A Focus on Technology, Tools & Advancing Therapies

Authors: Vallerie V. McLaughlin, MD (Chair); Jean M. Elwing, MD; Nicholas Kolaitis, MD, MAS; R. James White III, MD, PhDFaculty and Disclosures

CME Released: 3/30/2023

Valid for credit through: 3/30/2024

processing....

Assessment Survey

Before you begin, please take this brief survey.

  • Print